Publications by authors named "E Pawelka"
Age represents the major risk factor for fatal disease outcome in coronavirus disease (COVID-19) due to age-related changes in immune responses. On the one hand lymphocyte counts continuously decline with advancing age, on the other hand somatic hyper-mutations of B-lymphocytes and levels of class-switched antibodies diminish, resulting in lower neutralizing antibody titers. To date the impact of age on immunoglobulin G (IgG) production in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is unknown.
View Article and Find Full Text PDFArticle Synopsis
- Remdesivir is the only antiviral drug approved for hospitalized COVID-19 patients needing supplemental oxygen, but studies on its effect on mortality have shown mixed results.
- In this study, researchers compared hospitalized COVID-19 patients treated with remdesivir to controls, using a matching method to balance the groups, focusing on in-hospital mortality and length of stay.
- The overall results indicated no significant difference in mortality between the two groups, but subgroup analyses revealed lower mortality in women and in patients treated within 7 days of symptom onset, although patients treated with remdesivir had a longer hospital stay.
Background: Tocilizumab and baricitinib are recommended treatment options for hospitalized COVID-19 patients requiring oxygen support. Literature about its efficacy and safety in a head-to-head comparison is scarce.
Methods: Hospitalized COVID-19 patients requiring oxygen were treated with tocilizumab or baricitinib additionally to dexamethasone.
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone different molecular changes, sprouting genetic variants of the original wildtype. Clinical comparisons between patients infected with alpha versus delta are scarce.
Methods: In this retrospective observational study, adult patients hospitalized with coronavirus disease 2019 (COVID-19) due to confirmed SARS-CoV‑2 alpha or delta infection were included.
To date, no oral antiviral drug has proven to be beneficial in hospitalized patients with COVID-19. In this randomized, controlled, open-label, platform trial, we randomly assigned patients ≥18 years hospitalized with COVID-19 pneumonia to receive either camostat mesylate (CM) (considered standard-of-care) or lopinavir/ritonavir (LPV/RTV). The primary endpoint was time to sustained clinical improvement (≥48 h) of at least one point on the 7-category WHO scale.
View Article and Find Full Text PDF